@article{529db163779049b68d7f2cb5fbce4e3a,
title = "Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity",
abstract = "This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82\% accuracy (P < .001).",
author = "Ritchie, \{Marylyn D.\} and Haas, \{David W.\} and Motsinger, \{Alison A.\} and Donahue, \{John P.\} and Huso Erdem and Stephen Raffanti and Peter Rebeiro and George, \{Alfred L.\} and Kim, \{Richard B.\} and Haines, \{Jonathan L.\} and Sterling, \{Timothy R.\}",
note = "Funding Information: Financial support. The Vanderbilt Meharry Center for AIDS Research (funded by the National Institute of Allergy and Infectious Diseases [NIAID; grant P30 AI 54999]) and the NIAID (grant K23 AI01654 [to T.R.S.], grant HL65962 [to M.D.R.], and grant RR000095 to the Vanderbilt General Clinical Research Center).",
year = "2006",
month = sep,
day = "15",
doi = "10.1086/507101",
language = "English (US)",
volume = "43",
pages = "779--782",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",
}